797 Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel)
oleh: Joseph Markowitz, Siqing Fu, Gregory Daniels, Lyudmila Bazhenova, Nikhil Khushalani, Zeynep Eroglu, Andrew Brohl, Heather Yeckes-Rodin, Lori McCormick, Michael Kurman, Mireille Gillings, Gloria Lee
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2020-11-01 |
Deskripsi
No description available for this item.